摘要
目的探讨奈达铂所致不良反应发生的特点与一般规律,为临床合理使用奈达铂、预防与减少不良反应的发生与危害提供参考依据。方法对南通大学附属肿瘤医院2015年1~12月收集的119例奈达铂所致不良反应报告,从患者性别、年龄、原发病、上报人员、是否联合用药、用药剂量与不良反应发生的关系、对原发病的影响等方面进行回顾性分析。结果 119例不良反应中,严重不良反应有108例(90.75%),主要表现为骨髓抑制(89.08%),多发生于老年患者(67.22%),且多为联合用药(97.47%)。119例不良反应中,上报的主要为药师(88.23%)。大剂量单次给药的血液系统不良反应发生率与小剂量多次给药的血液系统不良反应发生率比较,差异无统计学意义(P>0.05)。结论奈达铂骨髓抑制发生率较高,临床应加强监测,尤其要关注老年患者,及时处理,并积极上报。医师可以根据患者的耐受性酌情使用小剂量多次给药或大剂量单次给药。
Objective To investigate the characteristics and general rules of adverse drug reactions induced by Nedaplatin, so as to provide reference for the clinical reasonable use of Nedaplatin and preventing or reducing the occurrence and harm of adverse drug reactions. Methods Total of 119 cases of adverse drug reaction reports induced by Nedaplatin collected in the Tumor Hospital Affiliated to Nantong University from January to December 2015 were ana- lyzed retrospectively from the aspects of patients＇ gender, age, primary illness, report personnel, drug combination or not, relationship between the dosage and the occurrence of adverse drug reactions, the influence on primary illness, and so on. Results Among 119 cases of adverse drug reaction, 108 cases （90.75%） had serious adverse drug reactions, which mainly showed myelosuppression （89.08%）, the occurrence was mainly happened in elderly patients （67.22%）, and the drug combination was the most （97.47%）. Among 119 cases, the mainly reported crowd was pharmacists （88.23%）. There was no statistically significant difference of the incidence of hematological toxicity of between single large dose delivery and multiple small dose delivery （P 〉 0.05）. Conclusion The incidence of myelosuppression of Nedaplatin is always high, which should be paid more attention, and disposed and reported in time, especially in elderly patients. The physician should use multiple small dose delivery or single large dose delivery according to the drug tolerance of patients.
作者
郭小红
卫榕
梅丹
徐艳艳
顾海娟
GUO Xiaohong WEI Rong MEI Dan XU Yanyan GU Haijuan(Department of Pharmacy, the Tumor Hospital Affiliated to Nantong University, Jiangsu Province, Nantong 226361, China)
出处
《中国医药导报》
CAS
2017年第5期141-144,168,共5页
China Medical Herald
基金
江苏省药学会-奥赛康临床药学基金科研项目(201515)
江苏省南通市卫生局青年医学人才科研基金项目(WQ2014042)
关键词
奈达铂
不良反应
合理用药
骨髓抑制
Nedaplatin
Adverse drug reaction
Reasonable drug use
Myelosuppression
